KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$5.9 million.

  • Bionano Genomics' Free Cash Flow rose 5566.91% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.7 million, marking a year-over-year increase of 7989.79%. This contributed to the annual value of -$69.0 million for FY2024, which is 4559.48% up from last year.
  • Bionano Genomics' Free Cash Flow amounted to -$5.9 million in Q3 2025, which was up 5566.91% from -$3.5 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Free Cash Flow registered a high of -$2.8 million during Q1 2025, and its lowest value of -$37.2 million during Q2 2023.
  • Over the past 5 years, Bionano Genomics' median Free Cash Flow value was -$26.3 million (recorded in 2021), while the average stood at -$21.5 million.
  • In the last 5 years, Bionano Genomics' Free Cash Flow crashed by 13968.64% in 2022 and then soared by 9005.58% in 2025.
  • Bionano Genomics' Free Cash Flow (Quarter) stood at -$26.3 million in 2021, then crashed by 37.35% to -$36.1 million in 2022, then increased by 15.37% to -$30.5 million in 2023, then soared by 78.69% to -$6.5 million in 2024, then increased by 9.29% to -$5.9 million in 2025.
  • Its Free Cash Flow was -$5.9 million in Q3 2025, compared to -$3.5 million in Q2 2025 and -$2.8 million in Q1 2025.